1-3 of 3
Ian Kirby
Close
Sort by
Journal Articles

Hematopoietic Stem Cells Expressing Engineered CD45 Enable a Near Universal Targeted Therapy for Hematologic Diseases

Romina Marone, Simon Garaudé, Rosalba Lepore, Anna Devaux, Astrid Beerlage, Federico Simonetta, Anna Camus, Izabela Durzynska, Ian Kirby, Patrick Van Berkel, Christian Kunz, Stefanie Urlinger, Lukas T Jeker
Journal: Blood
Blood (2023) 142 (Supplement 1): 3418.
https://doi.org/10.1182/blood-2023-173706
Published: 2023
Journal Articles

Development of Anti-CD45 Antibody Drug Conjugates As Targeted Conditioning Agents for Transplantation/Gene Therapy with Potent Anti-Leukemic Properties

Jenny Yeung, Aiyin Liao, Matthew Shaw, Soraia Caetano-Silva, Winston Vetharoy, Ian Kirby, Francesca Zammarchi, Karin Havenith, Patrick H van Berkel, Claire Booth, H Bobby Gaspar, Adrian J. Thrasher, Kerry Chester, Persis J Amrolia
Journal: Blood
Blood (2022) 140 (Supplement 1): 10211–10212.
https://doi.org/10.1182/blood-2022-162390
Published: 2022
Journal Articles

Striking Clinical, Molecular and Immunological Outcomes in Non-Human Primate Hematopoietic Stem Cell Transplantation Using a Novel OX40L Blockade Agent, KY1005, Combined with Rapamycin

Victor Tkachev, PhD, Scott N. Furlan, MD, Ben Watkins, MD, Betty Zheng, MD, Daniel Hunt, Angela Panoskaltsis-Mortari, PhD, Kayla Betz, Melanie Brown, Katie Zeleski, Alison Yu, PhD, Bruce R. Blazar, MD, Duncan Casson, Ian Kirby, Phil Bland-Ward, Leslie Kean, MD PhD
Journal: Blood
Blood (2016) 128 (22): 3341.
https://doi.org/10.1182/blood.V128.22.3341.3341
Published: 2016